Brainstorm Cell Therapeutics, Inc [BCLI] stock prices are up 0.81% to $1.25 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCLI shares have gain 15.74% over the last week, with a monthly amount glided 5.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Brainstorm Cell Therapeutics, Inc [NASDAQ: BCLI] stock has seen the most recent analyst activity on February 04, 2021, when Maxim Group upgraded its rating to a Buy but kept the price target unchanged to $12 for it. Previously, Maxim Group downgraded its rating to Hold on November 17, 2020. On December 19, 2016, Maxim Group reiterated its Buy rating and revised its price target to $6 on the stock. Maxim Group reiterated its Buy rating and decreased its price target to $5 on December 22, 2015.
The stock price of Brainstorm Cell Therapeutics, Inc [BCLI] has been fluctuating between $0.72 and $8.09 over the past year. Brainstorm Cell Therapeutics, Inc [NASDAQ: BCLI] shares were valued at $1.25 at the most recent close of the market.
Analyzing the BCLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -6.34, Equity is 2.03 and Total Capital is 1.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Brainstorm Cell Therapeutics, Inc [NASDAQ:BCLI]’s Current Ratio is 0.21. As well, the Quick Ratio is 0.21, while the Cash Ratio is 0.02.
Transactions by insiders
Recent insider trading involved Lebovits Chaim, President & CEO, that happened on Oct 01 ’24 when 1836.0 shares were purchased. President & CEO, Lebovits Chaim completed a deal on Sep 30 ’24 to buy 22000.0 shares. Meanwhile, Chief Medical Officer Dagher Ibrahim B. sold 63000.0 shares on Jul 19 ’24.
